Thursday, September 19, 2019
Home Partner Profiles Monitoring microcirculatory function with ODI Medical

Monitoring microcirculatory function with ODI Medical

Discover ODI Medical, the Norwegian start-up company that has quickly grown to a highly qualified team of 9 individuals, who have used a dynamic new approach to monitor microcirculatory function.

At ODI Medical, we use a completely new approach to monitor microcirculatory function. This way, we equip physicians with a powerful tool to accurately evaluate the health status of the patients, the likelihood of recovery and to test the efficacy of the provided treatment.

What do you know about ODI Medical?

ODI Medical is a Norwegian start-up company created in 2014 to leverage the 30 years of research in microcirculatory function from its founder, the Professor of Cardio-Thoracic surgery Knut Kvernebo, working at the University of Oslo. In just 4 years, ODI Medical has quickly grown to a highly qualified team of 9 individuals with a solid clinical and business background and many years of experience in a variety of academic, clinical, technical and business areas including clinical and translational research, clinical trials design and execution, medical technology, programming and development or business development.

We have developed a technology for bedside measurement and quantification of circulatory failure based on assessment of microcirculation. This technology is based in our proprietary “physiological biomarker” concept, the Oxygen Delivery Index™ (ODIN), which can  be used for a wide range of clinical applications such as monitoring patients on mechanical heart and lung machines, evaluation of toxicity of chemotherapy, early detection of evolving sepsis, monitoring of chronic wounds, and mass screening of conditions such as Ebola, bird flu or endemic meningitis.

The use of ODIN

ODIN can be used to make a diagnosis of the function of the circulatory system on an individual patient basis, to provide a prognosis for the specific patient and assess the efficacy of treatment in a specific patient by trend analyses of measurement before and after starting the treatment.

Finally, we have been able to get on board the world´s leading clinics as voluntary clinical partners to conduct our clinical trials for our first clinical application, ECMO patients (patients with acute heart failure being supported by heart and lung machines).

As a result of support from both institutional (e.g. The Research Council of Norway or Innovation Norway) and corporate funding bodies that have awarded us a combined 1 M€ in grants, we have been able to develop OXIMONITOR, the first-ever medical device accurately measuring microcirculatory function.

Learn more about the OXIMONITOR

The uniqueness of our developed platform does not only rely on using innovative optical technologies to fill the current gap found in microcirculation monitoring, but also the cutting-edge matching learning-driven Cloud computing platform that increases the clinical value of the patients’ results through accumulated data analysis.

With OXIMONITOR, the clinicians will be able to assess the function of microvascular beds nearly in almost real time at the patient’s bedside in an non-invasive and safe manner, equipping healthcare professionals with the following:

    1. A reliable diagnosis of the circulatory system function despite ECMO treatment;
    2. A patient’s prognosis (i.e. in case of recovery of heart function, decide whether the patient is offered a heart transplantation (HTx) or a left ventricular assist device (LVAD). In our proof-of-concept clinical trial, 100% of ECMO patients who survived showed ODIN measurements similar to healthy patients;
    3. A personalised assessment of whether the therapy of choice its working for the patient; and
    4. A safe (non-invasive) provides reproducible results even in newborns (already tested in real conditions).

The benefits to society

Diseases and conditions where microcirculatory function is largely impaired represent a major global health problem, a tremendous challenge for both the patient and their relatives, and a priority for regions such as Europe, since just considering AHF 2.7 million citizens die annually.

With OXIMONITOR we will commercialise a disruptive monitoring technology for which no reliable alternative is currently available, allowing for significant improvement of patient outcomes since healthcare professionals can choose the appropriate treatment that works best for each individual patient under consideration, thus maximising the chances of survival.

RECENT PUBLICATIONS

Profile in Health Europa quarterly, issue 9

Pin It on Pinterest